Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

On November 20, 2017, the Typhoid Vaccine Acceleration Consortium (TyVAC) vaccinated the first of 20,000 children against typhoid, successfully launching a study to assess the impact of typhoid conjugate vaccines (TCVs) in preventing typhoid among children in Nepal.

Photo: Bill & Melinda Gates Foundation/Sam Reinders

This vaccination study is part of TyVAC’s effort to generate evidence on TCV impact, and accelerate the use of TCVs in countries with significant typhoid burden. The study in Nepal is taking place over two years, and the results will inform future country introduction plans for the TCV. Successful introduction of the TCV in low-income countries that experience a high burden of typhoid, like Nepal, could potentially prevent many cases and deaths among children every year.

Before the study launched, project staff conducted extensive community outreach in the Kathmandu Valley, where it is taking place. Community support for the study is essential and activities ranged from staff going door-to-door and visiting local mothers’ groups to meetings with the district’s Public Health Division, mayor and other locally elected representatives. The project staff were also trained on a number of different topics, including cold chain management, vaccination administration, informed consent, data management and more, reflecting the effort that it takes to vaccinate 20,000 children in only three months.

The TCV being used in the study is the recently prequalified Typbar-TCV®. This new TCV has several advantages over earlier typhoid vaccines, including the potential ability to provide longer-lasting protection. It also requires fewer doses, and can be administered to children younger than two years of age, making it the first-ever typhoid vaccine to be approved for this age group. This is especially important, as children and adolescents younger than 15 years of age are disproportionately impacted by typhoid. As TyVAC continues to collect data, this will help gather evidence on how effective TCV is at preventing typhoid and potentially saving many children’s lives.

View more details in the photo story here - written by Rachel Colin-Jones.

 

Similar stories

Oxford University extends COVID-19 vaccine study to children

COVID-19 Research

The University of Oxford, together with three partner sites in London, Southampton and Bristol, is to launch the first study to assess the safety and immune responses in children and young adults of the ChAdOx1 nCoV-19 coronavirus vaccine.

World Health Organization experts provide guidance on use of the Oxford vaccine

COVID-19 Research

WHO SAGE says Oxford's coronavirus vaccine is safe and likely to be efficacious in older adults, and recommends its use in this age group.

Oxford leads first trial investigating dosing with alternating vaccines

COVID-19 Research

The Oxford Vaccine Group is to lead the first trial to explore alternating different COVID-19 vaccines, to explore the potential for flexibility in delivery and look for clues as to how to increase the breadth of protection against new virus strains.

Oxford vaccine stimulates broad antibody and T cell functions

COVID-19 Publication Research

Researchers from the University of Oxford have published further data from the Phase I/II clinical trials of the ChAdOx1 nCoV-19 coronavirus vaccine, evidencing the decision to move to a two-dose regimen in ongoing phase III trials, and how ChAdOx1 nCov-19 induces broad antibody and T cell functions.

SIMON Says…

Publication Research

Researchers at Oxford Vaccine Group have developed machine learning software to predict the efficacy of flu vaccines, offering huge potential for other vaccine research.